What question did this study set out to answer?

To explore the potential association between vedolizumab treatment and the occurrence of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

February 22, 2026Pediatric Dermatology1 citations

View Full Paper

Vedolizumab‐Associated Primary Cutaneous CD4 + Small/Medium T‐Cell Lymphoproliferative Disorder in a Biologic‐Naïve Pediatric Patient With Crohn's Disease

RGRomina GarakaniSt. Luke's University Health Network ZSZane SejdiuSt. Luke's University Health Network DCDevon CrossSt. Luke's University Health Network

Key Points

To explore the potential association between vedolizumab treatment and the occurrence of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.
Case report of an 11-year-old female with Crohn's disease
Monitoring of vedolizumab treatment for 12 months prior to lesion appearance
Assessment of symptoms related to skin lesions
Diagnosis of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder in the patient
Lesion development noted after initiation of vedolizumab treatment
Proposal that vedolizumab may have contributed to this rare condition

Abstract

ABSTRACT Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder (PCSM‐TCLPD) is a rare lymphoproliferative disorder that is occasionally diagnosed in children and adolescents. We present a case of PCSM‐TCLPD in an 11‐year‐old female with biologic‐naïve Crohn's disease well‐controlled on vedolizumab, which was initiated 12 months prior to lesion appearance. We propose that vedolizumab may have played a role in the development of PCSM‐TCLPD.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Garakani et al. (Fri,) studied this question.

synapsesocial.com/papers/699a9d7a482488d673cd3697 https://doi.org/https://doi.org/10.1111/pde.70169

Demander à l'IA

Bookmark

View Full Paper